Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
Clinical trial NCT06020989 · UNKNOWN
Trial details
- NCT number
- NCT06020989
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-01
- Primary completion
- 2024-09-01
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.